A detailed history of First Horizon Advisors, Inc. transactions in Castle Biosciences Inc stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 7,853 shares of CSTL stock, worth $223,967. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,853
Previous 7,853 -0.0%
Holding current value
$223,967
Previous $173,000 1.73%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 06, 2024

SELL
$12.19 - $22.43 $3,047 - $5,607
-250 Reduced 3.09%
7,853 $169,000
Q3 2023

Oct 27, 2023

BUY
$13.28 - $20.3 $8,924 - $13,641
672 Added 9.04%
8,103 $136,000
Q2 2023

Aug 03, 2023

BUY
$11.66 - $26.0 $5,153 - $11,492
442 Added 6.32%
7,431 $101,000
Q1 2023

May 15, 2023

BUY
$19.47 - $28.49 $350 - $512
18 Added 0.26%
6,989 $158,000
Q4 2022

Feb 10, 2023

SELL
$18.08 - $30.0 $4,646 - $7,710
-257 Reduced 3.56%
6,971 $164,000
Q3 2022

Nov 09, 2022

BUY
$22.51 - $34.32 $150,411 - $229,326
6,682 Added 1223.81%
7,228 $188,000
Q2 2022

Aug 02, 2022

SELL
$16.0 - $45.99 $832 - $2,391
-52 Reduced 8.7%
546 $11,000
Q1 2022

May 10, 2022

BUY
$33.17 - $46.98 $4,577 - $6,483
138 Added 30.0%
598 $27,000
Q4 2021

Feb 09, 2022

SELL
$39.06 - $67.58 $3,945 - $6,825
-101 Reduced 18.0%
460 $19,000
Q3 2021

Nov 15, 2021

SELL
$60.13 - $77.6 $26,336 - $33,988
-438 Reduced 43.84%
561 $37,000
Q3 2021

Nov 09, 2021

BUY
$60.13 - $77.6 $37,100 - $47,879
617 Added 161.52%
999 $66,000
Q2 2021

Aug 09, 2021

BUY
$50.07 - $76.78 $5,557 - $8,522
111 Added 40.96%
382 $28,000
Q1 2021

May 11, 2021

SELL
$58.92 - $97.33 $3,594 - $5,937
-61 Reduced 18.37%
271 $18,000
Q4 2020

Feb 11, 2021

BUY
$43.6 - $73.05 $6,496 - $10,884
149 Added 81.42%
332 $22,000
Q3 2020

Nov 12, 2020

BUY
$38.47 - $52.03 $7,040 - $9,521
183 New
183 $9,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $750M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.